| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
IN THIS ISSUE
| The first 10% of the full text of this article appears below. |
Screening Interval and Prostate Cancer Incidence
Screening asymptomatic men for prostate cancer has led to an increase in disease incidence. To determine whether the time between screening visits, the screening interval, has an effect on the rate of cancers detected between screening visits, Roobol et al. (p. 1296) analyzed data from two centers involved in the European Randomized Study of Screening for Prostate Cancer. As part of the study, 4,202 men in Gothenburg, Sweden, underwent screening at 2-year intervals, and 13,301 men in Rotterdam, the Netherlands, underwent screening at 4-year intervals. The 10-year cumulative incidence of prostate cancer was 13.14% in Gothenburg and 8.41% in Rotterdam. The cumulative
Breast Cancer, Hormone Use, and Mammography Screening
Trial of Hypnosis for Surgical Side Effects in Breast Cancer Patients
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia
OGR1 Acts as a Metastasis Suppressor in Prostate Cancer
H. pylori Genotype, Gastric Cancer, and Precancerous Gastric Lesions
Immune Supression and Squamous Cell Carcinoma of the Eye
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1340-1342.
J Natl Cancer Inst 2007 99: 1296-1303.
J Natl Cancer Inst 2007 99: 1304-1312.
J Natl Cancer Inst 2007 99: 1313-1327.
J Natl Cancer Inst 2007 99: 1335-1339.
J Natl Cancer Inst 2007 99: 1290-1295.
J Natl Cancer Inst 2007 99: 1328-1334.
J Natl Cancer Inst 2007 99: 1279-1280.
J Natl Cancer Inst 2007 99: 1280-1281.